You spent years developing your product. You navigated the regulatory process and earned your FDA clearance. Now revenue should follow, right? Not quite. For many MedTech companies, clearance marks the start of an entirely new challenge: getting the product to the people who need it. A strong medical device commercialization strategy is the difference between a product that sits on the shelf and one that genuinely changes patient outcomes.
The hard truth is that 75% of MedTech startups fail during the transition from research and development to commercial execution.1 Not because the technology was bad, but because they treated commercialization as an afterthought.
This post breaks down why that happens and what you can do differently.
The FDA Clearance Finish-Line Myth
FDA clearance (particularly a 510(k) clearance) means your product is substantially equivalent to something already on the market. It does not mean hospitals are waiting to order it, physicians are ready to switch, or that payers will reimburse it.
The clearance process is so demanding that many founders treat it as the end goal. In reality, reaching clearance with no commercial foundation in place is like qualifying for a race you have not trained for. The market does not reward you for getting there first; it rewards you for executing best.
Exit timelines tell a similar story. In 2024, 510(k) deals averaged 11.1 years from founding to exit, with PMA device deals reaching 13.8 years.2 Companies that move into commercialization without a plan simply extend that timeline, burning through runway in the process.
Why Most Medical Device Commercialization Strategies Fall Short
Failure at the commercial stage is rarely about the technology. It comes down to three patterns that appear again and again.
Marketing Gets Bolted On After Clearance
In most MedTech organizations, the marketing team is brought in after the 510(k) is filed. That leaves no time to build the foundation that drives early adoption: brand identity, competitive positioning, sales enablement materials, or a demand generation engine. When launch day arrives, companies scramble to look credible to an audience that has never heard of them.
The companies that scale fastest treat commercialization prep as parallel to the regulatory process, not sequential.
The Target Market Is Too Broad
Trying to reach everyone at once is one of the most common and most expensive mistakes in early-stage MedTech. A hospital system in the Midwest, an outpatient clinic in the South, and a large integrated health network have completely different procurement processes, clinical champions, and decision-making timelines.
Early success in a focused, well-defined segment creates real-world evidence, generates referrals, and builds the credibility needed to expand. A scattered approach produces noise, not traction.
Brand Identity Is Underdeveloped
Healthcare buyers are cautious by nature. They are evaluating whether they can trust you, not just your device. An inconsistent brand, an unclear value proposition, or a website that looks like it was built during the clinical trial phase signals that your organization is not ready for prime time.
Brand is not a vanity project in MedTech. It is the first proof point that your company can deliver on its promises.
What a Strong Medical Device Commercialization Strategy Looks Like
Effective commercialization is built on three interconnected pillars. They work best when developed together, not in isolation.
1. Operational Infrastructure First
Before any campaign goes live, your organization needs systems that support conversion and retention. That means CRM configuration, sales process documentation, onboarding workflows, and clear hand-offs between marketing and sales. Without this foundation, leads generated by marketing go nowhere.
Think of operational infrastructure as the plumbing behind the walls. Nobody sees it, but without it, nothing works.
2. A Brand That Earns Trust
Brand development in MedTech means more than a logo and a color palette. It means articulating why your product matters, who it helps, and why your company is the right team to deliver it. That story needs to live consistently across your website, your sales deck, your conference booth, and every touchpoint in between.
Physicians, procurement teams, and health system administrators all do their homework before recommending or purchasing a new device. A clear, consistent brand gives them confidence.
3. Precision-Driven Market Expansion
Once your operational foundation is solid and your brand is established, growth comes from expanding your audience with accuracy. That means identifying the right channels (clinical conferences, peer referrals, targeted digital campaigns) for your specific product and audience, and doubling down on what works.
Compliant marketing in healthcare requires a deep understanding of FDA promotion rules, off-label advertising restrictions, and payer communication guidelines. Getting this wrong is expensive; getting it right compounds over time.
How Long Does Commercialization Take?
There is a common perception gap here worth addressing. Research shows that 64% of pre-commercial companies developing Class II or III devices expect a six-plus year commercialization timeline. But only 29% of companies that have successfully launched products actually needed that long.3
The difference is preparation. Companies that enter the commercial phase with a defined strategy, a built-out brand, and a clear target segment move faster and spend less to do it. Companies that figure it out as they go extend the timeline and raise more money just to stay alive.
Commercialization is not a sprint or a marathon. It is a relay race, and each leg (operations, brand, market expansion) needs a runner ready before the baton is passed.
Frequently Asked Questions About Medical Device Commercialization
What is the difference between FDA clearance and FDA approval?
FDA clearance (510(k)) means a device is substantially equivalent to a legally marketed predicate device and can be sold in the United States. FDA approval (PMA) is required for higher-risk devices and involves a more rigorous review of clinical evidence. Neither clearance nor approval guarantees market adoption; that requires a separate commercialization effort.
How long does it take to commercialize a medical device after FDA clearance?
The timeline varies by market segment, product complexity, and commercial readiness. Industry data from 2024 shows 510(k) devices averaging 11.1 years from founding to exit.4 However, companies that enter the commercial phase with a defined strategy and built-out infrastructure can meaningfully compress that timeline.
What are the most common reasons FDA-cleared medical devices fail commercially?
The three most common failure points are: (1) marketing and brand development starting too late, leaving no time to build awareness before launch; (2) targeting too broad a market, which dilutes resources and slows traction; and (3) underdeveloped operational infrastructure, so incoming leads never convert. The underlying technology is rarely the problem.
Do I need a MedTech-specific marketing partner?
Yes, for most devices. Healthcare marketing operates under strict FDA promotion guidelines, off-label restrictions, and payer communication rules that general marketing agencies are not equipped to navigate. A partner with MedTech experience can build campaigns that are both effective and compliant, protecting you from regulatory risk while driving commercial results.
When should I start building my commercialization strategy?
As early as possible, ideally during the clinical trial phase. Brand development, market segmentation, and operational infrastructure all take time to build correctly. Companies that wait until clearance is in hand routinely find themselves 12 to 18 months behind where they need to be.
Turning Clearance Into Commercial Success
A FDA-cleared product is a remarkable achievement. But clearance is a starting line, not a finish line. A well-executed medical device commercialization strategy builds the operational foundation, brand credibility, and targeted market presence that converts regulatory milestones into real revenue.
The companies that scale are not necessarily the ones with the best technology. They are the ones who prepared for market as rigorously as they prepared for the FDA.
If your product is approaching clearance or has already cleared and you are figuring out what comes next, the sooner you build that foundation, the faster and more efficiently you will grow.
About Cicada
Cicada is a MedTech launch partner that helps FDA-cleared companies bridge the gap between clearance and commercial success. Through operational support, brand development, and precision-driven market expansion, Cicada aligns marketing, sales, and operations to build revenue-ready healthcare companies. Learn more at cicada.co.
1 FP&A Consulting. "Why the First 18 Months of Commercialization Kill 75% of Medtech Firms." https://fpnaconsulting.com/why-the-first-18-months-of-commercialization-kill-75-of-medtech-firms/
2 Nocturnal. "2024 Medical Device Investment Data: A Brighter Exit Path, A Challenging Funding Road." February 2025. https://nocturnalpd.com/2025/02/21/2024-medical-device-investment-data-a-brighter-exit-path-a-challenging-funding-road/
3 Greenlight Guru. "2025 Medical Device Industry Report." https://www.greenlight.guru/state-of-medical-device
4 Nocturnal, ibid.